Iconic Therapeutics racks up $48.5 mln Series C
Iconic Therapeutics, a clinical stage biopharmaceutical company focused on retinal disease and cancer, has secured an additional $10 million in Series C financing, bringing the total tally to $48.5 million. The investors included Xeraya Capital, MPM Capital, HBM Healthcare Investments, H.I.G. BioHealth Partners, Lundbeckfonden Ventures, Cormorant Asset Management and Osage University Partners.
9 August 2016•1 min read
